Iversen, LL. Consideration of the cathinones, Advisory Council on the Misuse of Drugs, 31 Mar 2010. 286 kB.
Meltzer, PC; Butler, D; Deschamps, JR; Madras, BK. 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (pyrovalerone) analogues: A promising class of monoamine uptake inhibitors. J. Med. Chem., 23 Feb 2006, 49 (4), 1420–1432. 179 kB. https://doi.org/10.1021/jm050797a
Casale, JF; Hays, PA. The characterization of α-pyrrolidinopentiophenone. Microgram J., 1 Jan 2012, 9 (1), 33–38. 1.2 MB. #α-Pyrrolidinopentiophenone MS,NMR,IR
Glennon, RA. Bath salts, mephedrone, and methylenedioxypyrovalerone as emerging illicit drugs that will need targeted therapeutic intervention. Adv. Pharmacol., 1 Jan 2014, 69, 581–620. 564 kB. https://doi.org/10.1016/B978-0-12-420118-7.00015-9
Byrska, B; Stanaszek, R; Zuba, D. Alpha-PVP as an active component of herbal highs in Poland between 2013 and 2015. Drug Test. Analysis, 1 Aug 2017, 9 (8), 1267–1274. 830 kB. https://doi.org/10.1002/dta.2151
EMCDDA. New drugs in Europe, 2015, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 May 2016. 1.0 MB.
EMCDDA. New drugs in Europe, 2014, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 Jul 2015. 879 kB.
EMCDDA. New drugs in Europe, 2011, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 Apr 2012. 401 kB.
Leffler, AM; Smith, PB; de Armas, A; Dorman, FL. The analytical investigation of synthetic street drugs containing cathinone analogs. Forensic Sci. Int., 1 Jan 2014, 234, 50-56. 973 kB. https://doi.org/10.1016/j.forsciint.2013.08.021
Zawilska, JB; Andrzejczak, D. Next generation of novel psychoactive substances on the horizon – A complex problem to face. Drug Alcohol Depend., 1 Jan 2015, 157, 1-17. 3.0 MB. https://doi.org/10.1016/j.drugalcdep.2015.09.030
Fornal, E. Study of collision-induced dissociation of electrospray-generated protonated cathinones. Drug Test. Analysis, 1 Jul 2014, 6 (7-8), 705-715. 527 kB. https://doi.org/10.1002/dta.1573 #22
Hyperlab. Hyperlab new compounds. 29 Sep 2014. 232 kB. Note: Contains links to hyperlab.info that require elevated access/karma to follow.
Gaspar, H; Bronze, S; Oliveira, C; Victor, BL; Machuqueiro, M; Pacheco, R; Caldeira, MJ; Santos, S. Proactive response to tackle the threat of emerging drugs: Synthesis and toxicity evaluation of new cathinones. Forensic Sci. Int., 1 Sep 2018, 290 146–156. 1.6 MB. https://doi.org/10.1016/j.forsciint.2018.07.001 #α-PVP MS,NMR
Yoshida, M; Suzuki, J; Nakajima, J; Nagashima, M; Takahashi, M; Uemura, N; Kanai, C; Moriyasu, T; Hamano, T; Nakae, D. Analysis of illegal drugs purchased in the fiscal year 2011. Ann. Rep. Tokyo Metr. Inst. P. H., 1 Jan 2012, 63 111–124. 575 kB. #α-PVP MS,NMR,UV
EMCDDA. Report on the risk assessment of 1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one (α-pyrrolidinovalerophenone, α-PVP), European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 Jul 2016. 735 kB. #α-PVP
Kavanaugh, PR; Biggers, Z. Competing constructions of bath salts use and risk of harm in two mediated contexts. Crime Media Cult., 22 Mar 2018, 1741659018763863. 774 kB. https://doi.org/10.1177/1741659018763863 #α-PVP
Simmons, SJ; Leyrer-Jackson, JM; Oliver, CF; Hicks, C; Muschamp, JW; Rawls, SM; Olive, MF. DARK classics in chemical neuroscience: Cathinone-derived psychostimulants. ACS Chem. Neurosci., 17 Oct 2018, 9 (10), 2379–2394. 1.6 MB. https://doi.org/10.1021/acschemneuro.8b00147 #α-PVP
Rickli, A; Hoener, MC; Liechti, ME. Monoamine transporter and receptor interaction profiles of novel psychoactive substances: Para-halogenated amphetamines and pyrovalerone cathinones. Eur. Neuropsychopharmacol., 1 Mar 2015, 25 (3), 365–376. 1.6 MB. https://doi.org/10.1016/j.euroneuro.2014.12.012 #α-PVP
Baumann, MH; Walters, HM; Niello, M; Sitte, HH. Neuropharmacology of synthetic cathinones. In New Psychoactive Substances : Pharmacology, Clinical, Forensic and Analytical Toxicology; Maurer, HH; Brandt, SD, Eds., Springer, Berlin, Heidelberg, 1 Jan 2018; pp 113–142. 409 kB. https://doi.org/10.1007/164_2018_178 #α-PVP
Luethi, D; Liechti, ME. Monoamine transporter and receptor interaction profiles in vitro predict reported human doses of novel psychoactive stimulants and psychedelics. Int. J. Neuropsychoph., 1 Oct 2018, 21 (10), 926–931. 254 kB. https://doi.org/10.1093/ijnp/pyy047 #S1 Cathinones α-PVP
Kronstrand, R; Guerrieri, D; Vikingsson, S; Wohlfarth, A; Gréen, H. Fatal poisonings associated with new psychoactive substances. In New Psychoactive Substances : Pharmacology, Clinical, Forensic and Analytical Toxicology; Maurer, HH; Brandt, SD, Eds., Springer, Berlin, Heidelberg, 1 Jan 2018; pp 495–541. 477 kB. https://doi.org/10.1007/164_2018_110 #Alpha-PVP
Yadav-Samudrala, BJ; Eltit, JM; Glennon, RA. Synthetic cathinone analogs structurally related to the central stimulant methylphenidate as dopamine reuptake inhibitors. ACS Chem. Neurosci., 1 Aug 2019, n/a. 354 kB. https://doi.org/10.1021/acschemneuro.9b00284 #3 NMR
Kraemer, M; Boehmer, A; Madea, B; Maas, A. Death cases involving certain new psychoactive substances: A review of the literature. Forensic Sci. Int., 1 May 2019, 298 186–267. 6.7 MB. https://doi.org/10.1016/j.forsciint.2019.02.021 #α-PVP
Bork, W; Dahlenburg, R; Gimbel, M; Jacobsen-Bauer, A; Zörntlein, S. Herleitung Von Grenzwerten Der „nicht Geringen Menge“ Im Sinne Des Btmg. Toxichem Krimtech, 1 Jan 2019, 86 (1), 5–91. 4.4 MB. #CA-009
Kolanos, R; Sakloth, F; Jain, AD; Partilla, JS; Baumann, MH; Glennon, RA. Structural modification of the designer stimulant α-pyrrolidinovalerophenone (α-PVP) influences potency at dopamine transporters. ACS Chem. Neurosci., 21 Oct 2015, 6 (10), 1726–1731. 767 kB. https://doi.org/10.1021/acschemneuro.5b00160 #7 NMR,other
Kolanos, R; Solis, E; Sakloth, F; De Felice, LJ; Glennon, RA. “Deconstruction” of the abused synthetic cathinone methylenedioxypyrovalerone (MDPV) and an examination of effects at the human dopamine transporter. ACS Chem. Neurosci., 18 Dec 2013, 4 (12), 1524–1529. 393 kB. https://doi.org/10.1021/cn4001236 #8 NMR,other